Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214716 | 0.87 | HIF1A (0.58) | NPC1NAMPT | |
| SCHEMBL5211695 | 0.85 | MEN1 (0.52) | ANO1 | |
| SCHEMBL5210926 | 0.85 | CYP3A4 (0.54) | HPGDROCK2LMNAADORA3ADORA2A | |
| SCHEMBL5210719 | 0.84 | CYP1A2 (0.66) | NPC1TP53ROCK2LMNAADORA3 | |
| SCHEMBL5212725 | 0.84 | HPGD (0.62) | HPGDTP53ROCK2LMNAADORA3 | |
| SCHEMBL5215582 | 0.83 | EPHX2 (0.57) | ROCK2ANO1 | |
| SCHEMBL8355117 | 0.83 | MMP13 (0.63) | HPGDNPC1TP53LMNAADORA3 | |
| Picolinic Acid Fluorobenzylamide SCHEMBL27812819 | 0.83 | TSHR (0.60) | HPGDTP53LMNACACNA1GCACNA1H | |
| SCHEMBL5209853 | 0.82 | ROCK2 (0.52) | NPC1ROCK2LMNAPOLBANO1 | |
| SCHEMBL5213910 | 0.82 | CA2 (0.54) | ROCK2LMNAADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | claimed |
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | claimed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | claimed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| EP-1530475-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6881743-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2004006931-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | HPGD 247/4885NPC1 3123/4885TP53 1698/4885 |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | HPGD 149/4885NPC1 1342/4885TP53 4761/4885 |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | HPGD 163/4885NPC1 1366/4885TP53 4789/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | HPGD 148/4885NPC1 2608/4885TP53 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.